审问,审讯
发表于 2025-3-23 10:16:39
U. Wollina,M. Gebhardt,D. Lange are capable of reproducibly predicting patient outcomes. Future management of bladder cancer will likely incorporate such prognostic molecular models for risk stratification and treatment personalization.
Fissure
发表于 2025-3-23 15:11:26
http://reply.papertrans.cn/39/3829/382805/382805_12.png
多样
发表于 2025-3-23 20:10:09
Molecular Prognostication in Bladder Cancer, are capable of reproducibly predicting patient outcomes. Future management of bladder cancer will likely incorporate such prognostic molecular models for risk stratification and treatment personalization.
Organization
发表于 2025-3-24 00:38:46
http://reply.papertrans.cn/39/3829/382805/382805_14.png
NATTY
发表于 2025-3-24 05:46:21
Carmen I. Hernandez Lara BS, PhDr greater certainty for cancer control, but at the risk of significant urinary and/or sexual morbidity. Conversely, AS preserves genitourinary function and quality of life in exchange for burdensome surveillance and the psychological impact of living with cancer.
陈列
发表于 2025-3-24 09:52:01
Miscellaneous Drug-related Adverse Effects,ous blood-based analytes, provide a method of patient evaluation with potential applications in virtually all disease states. In this review, we will describe current approaches with a particular focus on demonstrated clinical utility in the evaluation and management of prostate cancer.
不真
发表于 2025-3-24 13:52:54
http://reply.papertrans.cn/39/3829/382805/382805_17.png
预示
发表于 2025-3-24 18:08:11
http://reply.papertrans.cn/39/3829/382805/382805_18.png
SPURN
发表于 2025-3-24 22:18:16
http://reply.papertrans.cn/39/3829/382805/382805_19.png
纬线
发表于 2025-3-25 00:00:11
Advances in the Treatment of Metastatic Renal Cell Carcinoma,ad resurgence with the FDA approval of nivolumab with ipilimumab. In the current chapter, we attempt to contextualize available frontline therapies for metastatic renal cell carcinoma with a focus on the CABOSUN and CheckMate 214 clinical trials.